<DOC>
	<DOC>NCT00206674</DOC>
	<brief_summary>The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease.</brief_summary>
	<brief_title>Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease</brief_title>
	<detailed_description>On 29 May 2009, Bayer began transitioning the sponsorship of this trial to Genzyme. NOTE: This study was originally posted by sponsor Berlex, Inc. Berlex, Inc. was renamed to Bayer HealthCare, Inc.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Stable but active Crohn's disease at the time of screening Must be able to selfinject or have another person who can help with the injection Not have a colostomy or ileostomy Not be taking prohibited medications as defined in the protocol Not have had GI surgery or a bowel obstruction in the last 6 months or planned surgery for the next months Not have ever taken this drug or drugs of similar type in the past</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Morbus Crohn</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Phase III</keyword>
	<keyword>Placebo Controlled</keyword>
</DOC>